Enrich Pharma

Enrich Biopharma is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of novel small molecule therapeutics for oncology and autoimmune diseases. The company utilizes a proprietary drug discovery platform to develop highly selective inhibitors for validated but challenging biological targets, aiming to improve safety and efficacy profiles over existing treatments. Its lead candidate, EN002, is a highly selective Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical trials for indications including atopic dermatitis and rheumatoid arthritis. Enrich Biopharma's pipeline also includes EN005, a RORγt antagonist for inflammatory conditions, and several early-stage oncology programs. The company is backed by prominent venture capital firms such as Northern Light Venture Capital and Legend Capital.